Treatment of COVID-19 Patients Using Wharton’s Jelly-Mesenchymal Stem Cells
Brief Summary:The purpose of this study is to investigate the potential use of Wharton’s Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Use ofCélulas madre for COVID-19 Treatment | Biological: WJ-MSCs | Phase 1 |
Descripción detallada:
COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.
Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.
